Clinical Efficacy of Compound Tripterygium wilfordii Preparation（Xinfeng Capsules） in Improving Immune Inflammation of Rheumatoid Arthritis Due to Spleen Deficiency and Dampness Exuberance Based on Apriori Algorithm and Random Walk Model
10.13422/j.cnki.syfjx.20222171
- VernacularTitle:基于Apriori关联规则和随机行走模型研究复方雷公藤制剂（新风胶囊）改善类风湿关节炎脾虚湿盛证免疫炎症的临床疗效
- Author:
Ziheng ZHU
1
;
Lei WAN
2
;
Jian LIU
2
;
Chuanbing HUANG
2
;
Lei ZHAO
1
;
Yanyan FANG
2
;
Shu LI
1
;
Ximeng MA
1
;
Fangze LI
1
;
Saisai HU
1
;
Yingying CHEN
1
;
Jing CHENG
1
Author Information
1. Graduate School of Anhui University of Chinese Medicine， Hefei 230012， China
2. The First Affiliated Hospital of Anhui University of Chinese Medicine， Hefei 230031， China
- Publication Type:Journal Article
- Keywords:
Xinfeng capsules;
rheumatoid arthritis;
immunoinflammation;
spleen deficiency and dampness exuberance syndrome
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2023;29(5):32-38
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the effect of Xinfeng capsules on immunoinflammatory indicators in patients with rheumatoid arthritis （RA） due to spleen deficiency and dampness exuberance. MethodA total of 102 patients were randomly divided into control group and observation group according to the random number table method， with 51 cases in each group. All patients were treated with methotrexate tablets， while those in the observation group received additional Xinfeng capsules. The course of treatment in both groups was 12 weeks. The 28-joint disease activity score （DAS28）， visual analogue scale （VAS） scores， morning stiffness time， erythrocyte sedimentation rate （ESR）， high-sensitivity C-reactive protein （hs-CRP）， rheumatoid factor （RF）， anti-cyclic citrullinated peptide （anti-CCP） antibody， vascular endothelial growth factor （VEGF）， and serum amyloid A （SAA） of the two groups before and after treatment were compared. The efficacy and incidence of adverse events were compared between the two groups. The Apriori association rule model and random walk model were constructed to evaluate the effect of Xinfeng capsules in improving hs-CRP， ESR， RF， SAA， VEGF， and anti-CCP. ResultThere were no dropouts in this study. There was no statistical difference in the indicators between the two groups before treatment. After 12 weeks of treatment， the total effective rate in the observation group was 90.19% （46/51）， which was higher than 74.51% （38/51） in the control group （χ2＝4.320，P<0.05）. DAS28， VAS score， and morning stiffness time in the observation group were improved compared with those in the control group （P<0.05）. Apriori association rule model results showed that the application of Xinfeng capsules in the observation group had a strong correlation with the reduction of RF， ESR， hs-CRP， SAA， and VEGF. The results of the random walk model showed that the improvement coefficients of hs-CRP， ESR， RF， SAA， and VEGF in the observation group were all better than those of the control group， and the improvement coefficient of anti-CCP in the control group was better than that of the observation group. The improvement degree of hs-CRP， ESR， RF， SAA， and VEGF in the observation group was superior to that of the control group （P<0.05）. The incidence of adverse reactions in the observation group was lower than in the control group （χ2＝4.057，P<0.05）. ConclusionOn the basis of the treatment with methotrexate tablets， Xinfeng capsules can effectively improve the immunoinflammatory level in RA due to spleen deficiency and dampness exuberance and reduce the incidence of adverse reactions.
